NLS Pharmaceutics AG (NLSP)
1.48
-0.01 (-0.67%)
At close: Apr 04, 2025, 10:50 AM
Company Description
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders.
The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).
Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD.
The company was incorporated in 2015 and is based in Zurich, Switzerland.
NLS Pharmaceutics AG
| Country | CH |
| IPO Date | Jan 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Alexander Zwyer M.B.A. |
Contact Details
Address: The Circle 6 Zurich, CH | |
| Website | https://nlspharma.com |
Stock Details
| Ticker Symbol | NLSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001783036 |
| CUSIP Number | H57830103 |
| ISIN Number | CH0523961370 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander Zwyer M.B.A. | Co-Founder, Chief Executive Officer & Director |
| Nicole Fernandez-McGovern CPA | Chief Financial Officer |
| Dr. Eric Konofal M.D., Ph.D. | Co-Founder & Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | F-4/A | [Amend] Filing |
| Mar 31, 2025 | 425 | Filing |
| Mar 31, 2025 | 6-K | Filing |
| Mar 10, 2025 | 425 | Filing |
| Mar 10, 2025 | 6-K | Filing |
| Mar 03, 2025 | F-4/A | [Amend] Filing |
| Feb 27, 2025 | 6-K | Filing |
| Feb 25, 2025 | 425 | Filing |
| Feb 25, 2025 | 6-K | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |